Benefits of Hemodialysis Plus Hemoperfusion: A Clinical Study

Inclusion Criteria:

1. Age 18-80 years, regardless of gender

2. Stable maintenance hemodialysis for ≥ 3 months with relatively fixed dialysispattern

3. Hemodialysis treatment 3 times per week, total treatment duration ≥ 10 hours perweek, vascular access unlimited

4. Blood β2-MG > 30 mg/L and/or 300 pg/ml < immunoreactive parathyroid hormone (iPTH) < 800 pg/ml and/or CRP ≥ 16.2 pg/ml

5. Kt/V ≥ 1.2 eight weeks prior to enrollment

6. Signed informed consent form

Exclusion Criteria:

1. Known allergic reaction, contraindication or intolerance to the material of thedialyzer or perfusion apparatus

2. Test indicators meeting one or more of the following: white blood cell <4 x 10^9/L,platelet count <60 x 10^9/L, serum albumin <30 g/L

3. Blood flow <200 ml/min

4. Regular hemoperfusion treatment for more than 3 months and at least once every 2weeks

5. Active bleeding or chronic gastrointestinal bleeding, or other severe bleedingtendencies or coagulation disorders

6. History of unstable angina pectoris, myocardial infarction, severe arrhythmia,pericarditis, myocarditis, cardiac surgery or peripheral vascular surgery in thelast 8 weeks

7. Cerebral hemorrhage in the last 12 weeks

8. Severe heart failure (New York Heart Association class IV)

9. Acute infection, acute or critical illnesses such as severe cardiac, pulmonary,hepatic or neurological disease and malignancy

10. Pregnancy or breastfeeding

11. Participation in a clinical trial or ongoing clinical trial within 3 months

12. Expected survival of less than 1 year

13. Not considered suitable for participation in this trial by the investigator